5 results
to offer continuation of BIBF 1020 treatment for patients with IPF who have completed a prior clinical trial with that drug.establish the long term tolerability and safety profile of BIBF 1120 in IPF.
The aim of this extension trial is to provide BIBF 1120 treatment for all patients who have completed the 52 weeks treatment period and the follow up period in the phase III placebo controlled parent trial 1199.34, who may have experienced benefit…
The primary objective of this study is to compare the effects of bucindolol and metoprolol onthe recurrence of symptomatic AF/AFL in patients with HFREF who have a *1389 arginine homozygous(*1389Arg/Arg) genotype.The secondary objectives of this…
Primary objective: To assess the level of agreement between the following tests:- The minimal frequency difference necessary to evoke an ACC in normal hearing adults and adults with SNHL (ACC threshold).- The just noticeable frequency differences…
The objective of the trial is to confirm efficacy and a favorable benefit-risk ratio for BIBF 1120 in the treatment of IPF at the dose of 150 mg bid compared to placebo.